
WO41554
NCT04191499
JCP088
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC-0077 plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Patients with PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (INAVO120)
Status:
Recruiting

III
Phase

1st
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
HER2-, ER+, PIK3CA
Investigational
Product
GDC-0077
Selective PI3Kα-mutant inhibitor (p.o.)
Treatment Arms
o Experimental: GDC-0077 + Palbociclib + Fulvestrant
o Placebo Comparator: Placebo + Palbociclib + Fulvestrant